State of New Jersey Common Pension Fund D Has $1.92 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

State of New Jersey Common Pension Fund D decreased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 14.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,826 shares of the company’s stock after selling 14,973 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.09% of Intellia Therapeutics worth $1,921,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Avidity Partners Management LP increased its position in Intellia Therapeutics by 18.0% during the 4th quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock worth $13,642,000 after purchasing an additional 68,334 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Intellia Therapeutics by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after acquiring an additional 18,987 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $3,019,000. Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock valued at $254,514,000 after acquiring an additional 155,579 shares in the last quarter. Finally, Comerica Bank grew its position in Intellia Therapeutics by 853.6% during the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after acquiring an additional 33,214 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $21.88 on Friday. The stock’s 50-day moving average is $23.26 and its 200 day moving average is $24.12. Intellia Therapeutics, Inc. has a one year low of $19.21 and a one year high of $34.87. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -4.08 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. The business’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.40) EPS. On average, sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on NTLA. Stifel Nicolaus dropped their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial reissued a “buy” rating and set a $120.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.